Characterization of JAK2V617F and the JAK2 46/1 germline haplotype in myeloproliferative neoplasms in a Saudi Arabian cohort: a case-based analysis - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Analysis of JAK2V617F Mutation and JAK2 46/1 Germline Haplotype in Myeloproliferative Neoplasms Among a Saudi Arabian Population: A Case Study Approach
Clinical Scorecard: Analysis of JAK2V617F Mutation and JAK2 46/1 Germline Haplotype in Myeloproliferative Neoplasms Among a Saudi Arabian Population: A Case Study Approach
At a Glance
Category
Detail
Condition
Myeloproliferative Neoplasms (MPNs)
Key Mechanisms
JAK2V617F mutation and JAK2 46/1 haplotype as genetic predispositions
Target Population
Saudi Arabian population with MPNs
Care Setting
King Fahad Medical City, Riyadh, Saudi Arabia
Key Highlights
JAK2V617F mutation found in 13.1% of MPN patients.
80.7% of participants were carriers of the JAK2 46/1 haplotype.
Essential thrombocythemia (ET) showed the highest proportion of TT homozygotes (56.3%).
The study provides insights into genetic predisposition to MPNs in a Saudi cohort.
No significant difference in mutation frequency by sex.
Guideline-Based Recommendations
Diagnosis
Diagnosis and subtype categorization followed the 2016 WHO criteria.
Management
Monitoring & Follow-up
Risks
Increased risk of progression to acute myeloid leukemia (AML).
Patient & Prescribing Data
130 patients with MPN and 32 non-MPN controls.
Genetic profiling may inform risk stratification.
Clinical Best Practices
Consider genetic testing for JAK2V617F and JAK2 46/1 haplotype in MPN patients.
Utilize comprehensive driver mutation profiling in clinical assessments.
